Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Management of protease inhibitor-associated diarrhea.

Sherman DS, Fish DN.

Clin Infect Dis. 2000 Jun;30(6):908-14. Epub 2000 Jun 14. Review.

PMID:
10854364
2.

HIV-1 protease inhibitors.

Eron JJ Jr.

Clin Infect Dis. 2000 Jun;30 Suppl 2:S160-70. Review.

PMID:
10860901
3.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
4.

Management of protease inhibitor-associated hyperlipidemia.

Penzak SR, Chuck SK.

Am J Cardiovasc Drugs. 2002;2(2):91-106. Review.

PMID:
14727985
5.

Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.

Calza L, Manfredi R, Chiodo F.

J Antimicrob Chemother. 2004 Jan;53(1):10-4. Epub 2003 Nov 25. Review.

PMID:
14645323
6.

Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.

Bruno R, Sacchi P, Maiocchi L, Patruno S, Filice G.

Dig Liver Dis. 2006 Jun;38(6):363-73. Epub 2006 May 2. Review.

PMID:
16631422
7.

Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review.

Rhew DC, Bernal M, Aguilar D, Iloeje U, Goetz MB.

Clin Infect Dis. 2003 Oct 1;37(7):959-72. Epub 2003 Sep 12. Review.

PMID:
13130409
8.

[HIV infection, antiretroviral therapy, and endothelium].

Hürlimann D, Weber R, Enseleit F, Lüscher TF.

Herz. 2005 Sep;30(6):472-80. Review. German.

PMID:
16170677
9.
10.

The role of loperamide in gastrointestinal disorders.

Hanauer SB.

Rev Gastroenterol Disord. 2008 Winter;8(1):15-20. Review.

PMID:
18477966
11.

Atazanavir: a new protease inhibitor to treat HIV infection.

Musial BL, Chojnacki JK, Coleman CI.

Am J Health Syst Pharm. 2004 Jul 1;61(13):1365-74. Review. Erratum in: Am J Health Syst Pharm. 2004 Nov 1;61(21):2243.

PMID:
15287232
12.

Protease inhibitor-based regimens for HIV therapy: safety and efficacy.

Walmsley S.

J Acquir Immune Defic Syndr. 2007 Jun 1;45 Suppl 1:S5-13; quiz S28-31. Review.

PMID:
17525691
13.

Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors.

Sulkowski MS.

Semin Liver Dis. 2003 May;23(2):183-94. Review.

PMID:
12800071
14.

Nelfinavir mesylate.

Tebas P, Powderly WG.

Expert Opin Pharmacother. 2000 Dec;1(7):1429-40. Review.

PMID:
11249476
15.

Tolerability and safety of HIV protease inhibitors in adults.

Sax PE, Kumar P.

J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1111-24. Review. Erratum in: J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1434.

PMID:
15319670
16.

Management of HIV-associated diarrhea and wasting.

Winson SK.

J Assoc Nurses AIDS Care. 2001;12 Suppl:55-62. Review.

PMID:
11563238
17.

A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

Pinheiro Edos S, Antunes OA, Fortunak JM.

Antiviral Res. 2008 Sep;79(3):143-65. doi: 10.1016/j.antiviral.2008.05.001. Epub 2008 Jun 2. Review.

PMID:
18571246
18.

Disorders of glucose metabolism in patients infected with human immunodeficiency virus.

Dubé MP.

Clin Infect Dis. 2000 Dec;31(6):1467-75. Epub 2000 Nov 29. Review.

PMID:
11096014
19.

Protease inhibitor plasma concentrations in HIV antiretroviral therapy.

Justesen US.

Dan Med Bull. 2008 Nov;55(4):165-85. Review.

PMID:
19232158
20.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626

Supplemental Content

Support Center